US biotechnology company Novavax Inc (Nasdaq:NVAX) announced on Wednesday that the US Food and Drug Administration (FDA) has approved the Nuvaxovid 2025-2026 Formula for the prevention of COVID-19.
The formula was approved for adults aged 65 years and older, or individuals from 12 years with at least one underlying condition that puts them at high risk of severe outcomes from COVID-19.
Clinical and preclinical data have previously shown that Nuvaxovid is safe and effective for the prevention of COVID-19, and induces immunity across currently circulating JN.1 lineage strains, including NB.1.8.1, LP.8.1, XFG, XFC, LF.7 and XEC.
According to Novavax, Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the United States for the 2025-2026 vaccination season.
EpiVax introduces AI-enhanced models for immunogenicity prediction
Pfizer and BioNTech granted FDA approval for XFG-adapted COVID-19 vaccine
4basebio announces strategic collaboration with Genezen
Charles River and Medigen collaborate on next-generation enterovirus vaccine development
Piramal Pharma acquires controlling stake in Yapan Bio
Innorna Nominated for 2026 Prix Galien USA Best Startup Award
Sanofi's MenQuadfi receives EU approval for infants from six weeks
Evaxion to present three-year cancer vaccine data at ESMO Congress 2026
Evaxion presents new preclinical data on cytomegalovirus vaccine EVX-V1
Northwest Biotherapeutics presents on propensity score matching at BNOS 2026
Taiwan biomedical startups hold over 100 business meetings at BIO 2026
SK bioscience to lead Gates Foundation-funded ROTOR project
Anixa Biosciences' breast cancer vaccine technology granted first Korean patent
Transgene expands myvac platform into non-small cell lung cancer with TG4070